Format

Send to

Choose Destination
Cardiovasc Res. 2019 Mar 15;115(4):713-720. doi: 10.1093/cvr/cvz042.

Tumour necrosis factor superfamily members in ischaemic vascular diseases.

Author information

1
Heart Research Institute, 7 Eliza Street, Newtown, Sydney NSW, Australia.
2
School of Medical Sciences, University of Sydney, Camperdown, NSW, Australia.
3
Department of Biochemistry, University of Bath, Bath, UK.
4
Department of Cardiology, Royal Prince Alfred Hospital, Missenden Rd Camperdown, NSW, Australia.

Abstract

Current treatment of ischaemic vascular diseases such as coronary and peripheral artery disease includes angioplasty and bypass grafting, as well as lipid lowering therapies and control of other cardiovascular risk factors. Numerous members of the tumour necrosis factor superfamily (TNFSF) have recently shown emerging roles in both the protection and progression of such diseases. Understanding the role TNFSF members play in ischaemic vascular disease may provide insight into the development of novel therapeutics to prevent or treat diseases relating to atherosclerosis and ischaemia. This review summarizes the most recent findings relating to TNFSF members and the mechanisms that precede ischaemic vascular disease progression, particularly endothelial dysfunction, chronic inflammation, and atherosclerotic plaque development. This review also explores recent translational research on the role of TNFSF therapies in cardiovascular disease.

KEYWORDS:

Atherosclerosis ; Ischaemia ; TNF superfamily

PMID:
30816914
DOI:
10.1093/cvr/cvz042

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center